All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Semaglutide 0.5mg: Weight Loss Average

What is the average weight loss on semaglutide 0.5mg? Learn what the clinical trials showed, why results vary, and what factors influence your outcome.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Semaglutide 0.5mg: Weight Loss Average custom 2026 header image for GLP-1 Weight Loss
Custom header image for Semaglutide 0.5mg: Weight Loss Average, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Semaglutide 0.5mg: Weight Loss Average

What is the average weight loss on semaglutide 0.5mg? Learn what the clinical trials showed, why results vary, and what factors influence your outcome.

Short answer

What is the average weight loss on semaglutide 0.5mg? Learn what the clinical trials showed, why results vary, and what factors influence your outcome.

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, cash price and coverage terms

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

What is the average weight loss on semaglutide 0.5mg? Learn what the clinical trials showed, why results vary, and what factors influence your outcome.

If you're on semaglutide 0.5mg or about to move up to this dose, you're probably wondering how much weight you can realistically expect to lose. It's a fair question, and the clinical data gives us a useful starting point for understanding what this dose can do.

This guide covers what the clinical trials measured, how 0.5mg fits into the broader weight loss trajectory, and why your individual results may differ from the averages. As always, your physician is the best resource for setting realistic expectations based on your health profile.

How 0.5mg in the Dosing Hierarchy

Before looking at the numbers, it helps to understand where 0.5mg sits in the semaglutide treatment plan. In the STEP clinical trials, 0.5mg was the second step in a five-step escalation:

  • Weeks 1 through 4: 0.25mg once weekly
  • Weeks 5 through 8: 0.5mg once weekly
  • Weeks 9 through 12: 1.0mg once weekly
  • Weeks 13 through 16: 1.7mg once weekly
  • Week 17 onward: 2.4mg once weekly (maintenance)

The 0.5mg dose is a titration step, not a maintenance dose. participants in the clinical trials were not studied at 0.5mg for extended periods in isolation. The weight loss data we have reflects the cumulative effect of the entire dose-escalation protocol leading to the maintenance dose.

What the Clinical Trials Showed

The headline weight loss numbers from the STEP program reflect outcomes at the 2.4mg maintenance dose over 68 weeks. In STEP 1[1], participants lost an average of approximately 14.9% of their body weight compared to approximately 2.4% in the placebo group. For a complete cost breakdown, see our compare GLP-1 providers.

GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Semaglutide 0.5mg: Weight Loss Average

Weight loss during the 0.5mg phase (weeks 5 through 8) contributed to this overall outcome, but was a smaller portion of the total. Clinical trial data shows that weight loss with semaglutide is dose-dependent and time-dependent, with the most significant reductions occurring at higher doses and over longer treatment periods.

What to Expect During the 0.5mg Phase

While published trial data doesn't isolate weight loss specifically at each titration step, clinical experience and the dose-response relationship suggest that:

  • Most patients see modest weight loss during the 0.5mg phase, typically in the range of 1 to 3 percent of body weight when combined with the preceding 0.25mg phase.
  • Some patients notice a more significant response early, while others see minimal change until reaching higher doses.
  • The 0.5mg phase is still primarily about GI adaptation and building toward therapeutic levels, not maximal weight reduction.

How Semaglutide Produces Weight Loss

About the mechanism helps explain why weight loss is dose-dependent. Semaglutide works through several pathways:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
  • Appetite regulation: It acts on GLP-1 receptors in the brain to reduce hunger signals and increase feelings of fullness. At 0.5mg, this effect is present but typically less pronounced than at higher doses.
  • Delayed gastric emptying: Food stays in the stomach longer, contributing to early satiety. This effect is active at 0.5mg and contributes to reduced food intake.
  • Metabolic effects: Semaglutide influences insulin secretion and glucose metabolism, which can have indirect effects on fat storage and energy use.

As the dose increases through the titration schedule, these effects intensify, which is why weight loss tends to accelerate at higher doses.

Why Your Results May Differ From the Average

Clinical trial averages are just that: averages. In any study, there's many individual outcomes. Some participants lost significantly more than 14.9%, while others lost less. Several factors influence where you fall on that spectrum:

  • Starting weight: Patients with a higher initial body weight may lose more in absolute terms (pounds) but a similar or lower percentage of body weight.
  • Diet and nutrition: Semaglutide works best alongside a reduced-calorie diet. Patients who make meaningful dietary changes tend to see better outcomes.
  • Physical activity: Regular exercise supports weight loss and helps preserve lean muscle mass during treatment.
  • Metabolic factors: Insulin resistance, thyroid function, hormonal status, and baseline metabolic rate all affect the pace of weight loss.
  • Medication adherence: Consistent, on-schedule injections matter. Missing doses or irregular timing can reduce the medication's effectiveness.
  • Genetics: Individual genetic variation influences how your body responds to GLP-1 receptor agonists.
  • Sleep and stress: Poor sleep and chronic stress can impair weight loss through hormonal pathways that affect metabolism and appetite.

What Affects Your Weight Loss at 0.5mg

  • How long you stay at this dose: Patients who spend extra time at 0.5mg (beyond the standard four weeks) may see more weight loss at this level, though the rate may be modest compared to higher doses.
  • Your response to 0.25mg: If you already experienced noticeable appetite changes during the introductory phase, 0.5mg may build on that foundation more effectively.
  • Caloric intake: Even with appetite suppression, caloric intake matters. Working with a nutritionist or following your physician's dietary guidance can improve results.
  • Hydration: Adequate water intake supports metabolism and helps manage GI side effects that could otherwise disrupt your eating patterns.
  • Body composition: Patients with more fat mass relative to lean mass may respond differently than those with a different composition.

Setting Realistic Expectations

It's important to approach the 0.5mg phase with the right mindset. This dose is part of a process, not the destination. Here are some grounding points:

  • The most dramatic weight loss results reported in headlines typically reflect outcomes after months at the maintenance dose, not during early titration.
  • Weight loss that's steady and gradual is more likely to be sustainable than rapid drops.
  • Non-scale victories matter. Improved energy, better blood sugar control, reduced cravings, and improved relationship with food are all meaningful outcomes, even before the number on the scale changes significantly.
  • Comparing your progress to others isn't helpful. Individual biology makes every response unique.

Safety Considerations

While pursuing weight loss, keep these safety points in mind:

  • Losing weight too quickly can increase the risk of gallbladder issues, including gallstones. Report any sudden upper abdominal pain to your physician.
  • Ensure adequate protein intake to help preserve lean muscle mass during weight loss. Your physician or a registered dietitian can help you set targets.
  • Don't skip meals to accelerate results. Severe caloric restriction combined with semaglutide can lead to nutrient deficiencies, fatigue, and other complications.
  • Stay hydrated, especially if you experience any GI side effects.
  • Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Frequently Asked Questions

Is it normal to not lose weight at 0.5mg?

Yes, this is within the range of normal. The 0.5mg dose is a titration step, and some patients don't see significant weight loss until reaching higher doses. If you're tolerating the medication well and following your treatment plan, your physician will guide you through the escalation process.

How much weight should I expect to lose per week at 0.5mg?

There's no universal weekly target. Weight loss at this dose is generally modest and varies widely. Some patients may lose 0.5 to 1 pound per week during this phase, while others may see little change. Focus on the long-term trajectory rather than weekly numbers.

Will I lose more weight when my dose increases?

Clinical data strongly supports a dose-dependent weight loss effect with semaglutide. Most patients see their weight loss accelerate as they move to higher doses, particularly at 1.7mg and 2.4mg. Your physician will guide the pace of escalation.

Should I diet aggressively to maximize results at 0.5mg?

No. Extreme caloric restriction isn't recommended and can be counterproductive. A moderate, balanced, reduced-calorie diet combined with physical activity is the approach supported by clinical trial data. Work with your physician or a dietitian to set appropriate targets.

Do the clinical trials account for diet and exercise?

Yes. Participants in the STEP trials received lifestyle counseling that included a reduced-calorie diet and increased physical activity. The weight loss results reflect the combination of medication plus lifestyle changes, not medication alone.

Medical References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]

Track Your Progress With FormBlends

At FormBlends, our physicians set realistic expectations from day one. We track your progress throughout the titration process and help you understand what each dose is designed to accomplish. Weight loss is a process, and we're here to guide every step.

Ready to start your weight loss plan? Schedule a consultation with a FormBlends physician today.

Disclaimer: This content is for educational purposes only and doesn't constitute medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider before starting, stopping, or changing any medication. Individual results vary. Semaglutide is a prescription medication and should only be used under the supervision of a licensed healthcare provider.

Talk to a licensed provider

Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.

Start the assessment →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Semaglutide 0.5mg: Weight Loss Average, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

Semaglutide 0.5mg: Weight Loss Average is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

FormBlends Editorial Context

Reviewed May 14, 2026

What is the average weight loss on semaglutide 0.5mg? Learn what the clinical trials showed, why results vary, and what factors influence your outcome. "Semaglutide 0.5mg: Weight Loss Average" is meant to make a complicated topic easier to discuss, not to flatten it into a one-size answer. FormBlends frames it around patient education and clinical context, with extra attention to semaglutide, provider access. Because this article has 9 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. If the next step affects treatment or sourcing, use the article to prepare questions for a licensed clinician.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Semaglutide 0.5mg

Semaglutide 0.5mg now carries extra 2026 context around semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, 5mg, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.

Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to semaglutide 0 5mg weight loss average.

Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.

Semaglutide 0.5mg custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Semaglutide 0.5mg, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Semaglutide 0.5mg, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.